FDA clearance
Dartmouth Spinoff Episteme Prognostics Aims to Bring Precision Epigenetics to Pancreatic Cancer
Premium
The researchers at the startup have developed a microarray test to predict patients' response to chemotherapy based on chromatin accessibility.
FDA Approves Amgen's Lumakras for NSCLC Alongside Companion Tests From Guardant Health, Qiagen
The approval makes Lumakras the first inhibitor of KRAS, once considered "undruggable," to reach the market for KRAS-mutated NSCLC.
FDA Clears IND for Kinnate Biopharma's RAF Inhibitor KIN-2787
The firm plans to begin evaluating the agent as a first-line treatment for BRAF-mutated solid cancers in a Phase I/II clinical trial slated for mid-2021.
Amid more tests, drugs, and emerging evidence, commercial insurance coverage for comprehensive genomic profiling remains inconsistent, contributing to access disparities.
The autologous, anti-BCMA CAR T-cell therapy may be the first to garner FDA approval for multiple myeloma patients but competing products may soon catch up.